Matinas BioPharma Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders??? Equity (Details Narrative)

Stockholders’ Equity (Details Narrative)											1 Months Ended		12 Months Ended
Stockholders’ Equity (Details Narrative)	Jul. 02, 2020 shares	Jun. 19, 2020 shares	Jan. 14, 2020 USD ($) $ / shares	Jan. 14, 2020 USD ($) $ / shares shares	Jul. 29, 2019	Jun. 19, 2019 shares	Mar. 28, 2019 USD ($) $ / shares shares	Mar. 19, 2019 USD ($) $ / shares shares	Jun. 21, 2018 USD ($) $ / shares shares	Jun. 19, 2018 $ / shares shares	Jan. 31, 2021 USD ($) shares	Jan. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) $ / shares shares	Dec. 31, 2015 shares
Subsidiary, Sale of Stock [Line Items]
Net proceeds from public offering of common stock \| $				$ 50,000,000.0									$ 46,704,210	$ 30,103,306
Preferred stock shares authorized													8,000	8,000
Preferred stock par value \| $ / shares													$ 1,000	$ 1,000
Number of warrant to purchase of common stock													1,327,810
Preferred stock, shares outstanding													4,361	4,577
Common stock, shares outstanding													200,113,431	163,156,984
Number of warrants issued													1,737,000		20,000,000
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of warrants description													the Company may call the warrants at any time the common stock trades above $3.00 for twenty (20) consecutive days
Series A Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock shares authorized													10,000,000
Preferred stock par value \| $ / shares													$ 0.001
Dividend rate					8.00%
Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock shares authorized										8,000
Number share issued upon conversion													216	242
Preferred stock, shares outstanding													4,361	4,577
Number of preferred stock shares converted													2,000
Stock conversion percentage													0.501
Beneficial ownership limitation description													The Company may not affect any optional or automatic conversion of the Series B Preferred Stock, or issue shares of common stock as dividends and a holder does not have the right to convert any portion of the Series B Preferred Stock to the extent that, after giving effect to such conversion such holder would beneficially own in excess of the Beneficial Ownership Limitation, or such holder, together with such holder’s affiliates, and any persons acting as a group together with such holder or affiliates, would beneficially own in excess of the Beneficial Ownership Limitation. The “Beneficial Ownership Limitation” is 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the issuance of shares of common stock issuable upon conversion of Series B Preferred Stock held by the applicable holder. A holder may, prior to issuance of the Series B Preferred Stock or, with 61 days prior notice to us, elect to increase or decrease the Beneficial Ownership Limitation; provided, however, that in no event may the Beneficial Ownership Limitation exceed 9.99%.
Liquidity value and dividends, description													(i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on the 12 month anniversary of the COD Effective Date, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on the 24-month anniversary of the COD Effective Date and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on the 36-month anniversary of the COD Effective Date. In the event a purchaser in this offering no longer holds Series B Preferred Stock as of the 12-month anniversary, the 24-month anniversary or the 36-month anniversary, such purchaser will not be entitled to receive any dividends on such anniversary date. Based on an accounting of the holders of record of Series B Preferred Stock on June 19, 2019 and 2020, the Company paid the 12-month anniversary dividend payments of 10% and 15%, respectively, totaling 946,000 shares and 1,365,600 shares, respectively, of common stock.
Dividend rate		15.00%				10.00%
Common stock, shares outstanding		1,365,600				946,000
Liquidation value of preferred share value \| $ / shares													$ 1,000
Holders [Member] \| Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion price per share \| $ / shares													$ 0.50
Number of preferred stock shares converted													8,722,000
Lab Equipment [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock shares							2,199,259	27,272,727
Net proceeds from public offering of common stock \| $							$ 2,300,000	$ 27,800,000
Price per share \| $ / shares							$ 1.10	$ 1.10
Gross proceeds from offering \| $								$ 30,000,000.0
Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights \| $ / shares													$ 0.50
Maximum [Member] \| Lab Equipment [Member] \| Underwriters [Member]
Subsidiary, Sale of Stock [Line Items]
Number of options to purchase common stock								4,090,909
Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights \| $ / shares													$ 0.75
Merger Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Net proceeds from public offering of common stock \| $				$ 46,700,000
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of underwritten public offering of common stock				32,300,000									32,260,000	29,471,986
Purchase price \| $ / shares			$ 1.55	$ 1.55
Common Stock [Member] \| Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Options to purchase an additional shares of common stock				4,800,000
Designated [Member] \| Series A Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock shares authorized													1,600,000
Sales Agreement [Member] \| Subsequent Event [Member] \| Common Stock [Member] \| Lab Equipment [Member]
Subsidiary, Sale of Stock [Line Items]
Net proceeds from public offering of common stock \| $												$ 5,600,000
Number of underwritten public offering of common stock												3,023,147
Placement Agency Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Gross proceeds from common stock \| $									$ 8,000,000
Net proceeds of shares issued \| $									$ 7,100,000
Percentage of gross proceeds									7.00%
Percentage of non- accountable expenses									1.00%
Placement Agency Agreement [Member] \| Series B Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock shares										8,000
Preferred stock par value \| $ / shares										$ 0.0001
Preferred stock stated value \| $ / shares										$ 1,000
Placement Agency Agreement [Member] \| Maximum [Member] \| Series B Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of underwritten public offering of common stock										7,200,000
Number share issued upon conversion										16,000,000
Placement Agency Agreement [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion price per share \| $ / shares										$ 0.50
Placement Agency Agreement [Member] \| Two Thousand Eighteen Placement Agent Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Number of warrant to purchase of common stock									240,000
Fair value of warrants \| $									$ 89,000,000
Warrant term									5 years
Class of warrant or right, exercise price of warrants or rights \| $ / shares									$ 0.75
Underwritten Public Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Net proceeds from public offering of common stock \| $			$ 46,700,000					$ 27,800,000
Underwritten Public Offering [Member] \| Sales Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock shares	50,000,000
Sale of stock percentage	3.00%
Underwritten Public Offering [Member] \| Sales Agreement [Member] \| Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock shares											3,023,147
Gross proceeds from common stock \| $											$ 5,800,000
Net proceeds from public offering of common stock \| $											$ 5,600,000